Ultrasonic-Strip (U-Strip) Transdermal Insulin Delivery System for Treating Diabetes

Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.

Anticipated Utilization: 1(Expected to be used by <20% of patients with anticipated indications)

Transdermal insulin delivery systems could replace traditional means of insulin delivery (e.g., injection, subcutaneous infusion pumps) because they are noninvasive and needle-free. According to the U.S. Centers for Disease Control and Prevention, about 5.8 million adults with diabetes (approximately 27.9% of the diabetes population) were self-administering insulin as of 2011. As many as 2.3 million to 3.5 million of these individuals might opt to use a transdermal insulin delivery system. Factors such as the availability of newer "painless" needles and improved pharmacotherapeutic options, as well as the cost, reimbursement, safety, and efficacy of the U-Strip™ (Ultrasonic Strip) (Transdermal Specialties, Inc., Norwalk, CT, USA) will affect diffusion.

Estimated Adoption Status: 1(Early...